[email protected]

USA: +1 347 690-0211 | UK: +44 2032 894158 | Translate : 

Search Market Research Report

Discover Our Latest Reports
Discover Our Featured Reports
Discover Top Selling Reports
  1. Home
  2. Healthcare
  3. Fabry Disease Treatment Market

Fabry Disease Treatment Market Size, Share, Global Trends, Forecast to 2020-2026

report img

Fabry Disease Treatment Market by Drugs (Agalsidase Beta, Migalastat, and Pipeline Drugs), By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), and Others), By Route of Administration (Oral, and Intravenous) and By Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

Industry Insights

[195+ Pages Report] According to the report published by Facts and Factors, the global fabry disease treatment market size was valued around USD 1.77 billion in 2019 and is expected to grow to around USD 3.78 billion by 2026 with a compound annual growth rate (CAGR) of roughly 9.83% between 2020 and 2026. The report analyzes the global fabry disease treatment market drivers, challenges, and the impact they have on the demands during the forecast period. In addition, the report explores emerging opportunities in the fabry disease treatment market.

Fabry Disease Treatment Market Size

To know more about this report | Request Free Sample Copy

logoMarket Overview       

Fabry disease is an X-linked lysosomal storage condition. The deficiency of the alpha-galactosidase enzyme in a patient causes progressive organ dysfunction. The development of Fabry diseases is primarily caused by an abnormal accumulation of a particular fatty matter known as globotriaosylceramide. The skin, heart, eyes, brain, kidneys, central nervous system, and gastrointestinal system are all affected by this irregular accumulation.

logoIndustry Growth Factors

The treatment's main goal is to reduce and alleviate the patients' crippling discomfort while also preventing disease progression. Fabry's disease cannot be cured, but the harm it causes can be reduced with proper treatment. In the year 2003, the FDA approved the intravenous administration of Agalsidase as an enzyme replacement therapy (ERT) for the treatment of Fabry's disease. Before that, patients were given carbamazepine and diphenylhydantoin to relieve pain, and their estimated lifespan was between 40 and 50 years. The use of new treatments such as substrate replacement therapy and chaperone treatment has risen rapidly in recent years. However, enzyme replacement therapy has long been the most popular treatment, with a large market share that is expected to sustain during the forecast period.

The market is growing as the number of patients suffering from Fabry disease is increasing. Aside from that, broad R&D activities and the potential approval and launches of promising pipeline products such as substrate decline treatments and compound replacement treatments are expected to boost the industry's growth over the forecast period. In addition, the market is expected to expand due to the legalization of oral chaperone therapy in developing countries and the advancement of gene therapy. Additionally, due to patent expirations, the proliferation of biosimilars is expected to increase during the forecast era. Patients with Fabry disease often experience strokes, excruciating pain, an early heart condition, impaired kidney function, which may contribute to kidney failure, and debilitating gastrointestinal symptoms. Since there is no cure for Fabry disease, care focuses on managing complications associated with disease progression and providing symptomatic relief. Various patients are often misdiagnosed due to mild symptoms. The global Fabry disease market is expected to expand at a significant pace in the coming years as a result of these factors.

Fabry Disease Treatment Market

To know more about this report | Request Free Sample Copy

logoSegmentation Analysis

The global Fabry disease treatment Market is segregated into drugs, route of administration, treatment, and regions.  The drug category is segmented into migalastat, agalsidase beta, and pipeline drugs. The pipeline drugs are expected to hold highest market share in 2019. Based on treatment, the market has been categorized into substrate reduction therapy, chaperone treatment, enzyme replacement therapy, and others. Both Shire's Replagal, and Sanofi's Fabrazyme have received European approval, only Fabrazyme has received approval in the United States. Current clinical trials are focusing on improving the safety and efficacy profile of ERTs, as well as the development of innovative oral therapies that can replace intravenous infusions.

The segment's dominance is supported by strong sales of Fabrazyme and Replagal, as well as the possible acceptance of successful pipeline candidates. However, the introduction of new, more effective treatment methods, such as gene therapy, is critical for a significant improvement in patient benefits. In terms of route of administration, the market has been segregated into oral, and intravenous.

logoReport Scope

Report Attribute

Details

Market Size in 2019

USD 1.77 Billion

Projected Market Size in 2026

USD 3.78 Billion

CAGR Growth Rate

9.83% CAGR

Base Year

2019

Forecast Years

2020-2026

Key Market Players

ISU Abxis Co Ltd., Greenovation Biotech GmbH, Amicus Therapeutics Inc., Avrobio Inc., Shire Plc., Sanofi S.A.,  Moderna Therapeutics Inc., JCR Pharmaceuticals, Protalix Biotherapeutics Inc., and Idorsia Pharmaceuticals Ltd., amongst others.

Key Segment

By Drugs, Treatment, Route, and Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs.Explore purchase options

logo Regional Analysis

Due to various expanding human service use and developing infrastructure, Asia Pacific offers major growth opportunities for pharmaceutical companies. Because of the large populations in emerging countries, the region is expected to grow the fastest in the coming years, followed by Latin America. In 2018, North America surpassed Europe as the most important regional market.

Increased availability of innovative therapies, improved social insurance offices, and favorable reimbursement terms are all playing important roles in the region's business growth. Inclusion of expensive medications like Fabrazyme by health insurance plans, as well as favorable regulatory medicinal services arrangements, are also encouraging pharmaceutical companies to increase R&D activity in the field of rare diseases.

logo Competitive Players

Some main participants of the global Fabry disease treatment market are:

  • ISU Abxis Co Ltd.
  • Greenovation Biotech GmbH
  • Amicus Therapeutics Inc.
  • Avrobio Inc.
  • Shire Plc.
  • Sanofi S.A.
  • Moderna Therapeutics Inc.
  • JCR Pharmaceuticals
  • Protalix Biotherapeutics Inc.
  • Idorsia Pharmaceuticals Ltd.

The global Fabry disease treatment market is segmented as follows:

logoBy Drugs:

  • Agalsidase Beta
  • Migalastat
  • Pipeline Drugs

logoBy Treatment:

  • Enzyme Replacement Therapy (ERT)
  • Chaperone Treatment
  • Substrate Reduction Therapy (SRT)
  • Others

logoBy Route of Administration:

  • Oral
  • Intravenous

logoFabry Disease Treatment Market: Regional Segment Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of MEA

Table of Content

  1. Chapter 1 Executive Summary
    1. 1.1. Introduction of Fabry Disease Treatment
    2. 1.2. Global Fabry Disease Treatment Market, 2019 & 2026 (USD Million)
    3. 1.3. Global Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    4. 1.4. Global Fabry Disease Treatment Market Absolute Revenue Opportunity, 2016 – 2026 (USD Million)
    5. 1.5. Global Fabry Disease Treatment Market Incremental Revenue Opportunity, 2020 – 2026 (USD Million)
  2. Chapter 2 Fabry Disease Treatment Market – Drugs Analysis
    1. 2.1. Global Fabry Disease Treatment Market – Drugs Overview
    2. 2.2. Global Fabry Disease Treatment Market Share, by Drugs, 2019 & 2026 (USD Million)
    3. 2.3. Agalsidase Beta
      1. 2.3.1. Global Agalsidase Beta Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    4. 2.4. Migalastat
      1. 2.4.1. Global Migalastat Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    5. 2.5. Pipeline Drugs
      1. 2.5.1. Global Pipeline Drugs Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
  3. Chapter 3 Fabry Disease Treatment Market – Treatment Analysis
    1. 3.1. Global Fabry Disease Treatment Market – Treatment Overview
    2. 3.2. Global Fabry Disease Treatment Market Share, by Treatment, 2019 & 2026 (USD Million)
    3. 3.3. Enzyme Replacement Therapy (ERT)
      1. 3.3.1. Global Enzyme Replacement Therapy (ERT) Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    4. 3.4. Chaperone Treatment
      1. 3.4.1. Global Chaperone Treatment Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    5. 3.5. Substrate Reduction Therapy (SRT)
      1. 3.5.1. Global Substrate Reduction Therapy (SRT) Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    6. 3.6. Others
      1. 3.6.1. Global Others Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
  4. Chapter 4 Fabry Disease Treatment Market – Route of Administration Analysis
    1. 4.1. Global Fabry Disease Treatment Market – Route of Administration Overview
    2. 4.2. Global Fabry Disease Treatment Market Share, by Route of Administration, 2019 & 2026 (USD Million)
    3. 4.3. Oral
      1. 4.3.1. Global Oral Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    4. 4.4. Intravenous
      1. 4.4.1. Global Intravenous Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
  5. Chapter 5 Fabry Disease Treatment Market – Regional Analysis
    1. 5.1. Global Fabry Disease Treatment Market Regional Overview
    2. 5.2. Global Fabry Disease Treatment Market Share, by Region, 2019 & 2026 (USD Million)
    3. 5.3. North America
      1. 5.3.1. North America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
        1. 5.3.1.1. North America Fabry Disease Treatment Market, by Country, 2016 - 2026 (USD Million)
      2. 5.3.2. North America Fabry Disease Treatment Market, by Drugs, 2016 – 2026
        1. 5.3.2.1. North America Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      3. 5.3.3. North America Fabry Disease Treatment Market, by Treatment, 2016 – 2026
        1. 5.3.3.1. North America Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      4. 5.3.4. North America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026
        1. 5.3.4.1. North America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      5. 5.3.5. U.S.
        1. 5.3.5.1. U.S. Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      6. 5.3.6. Canada
        1. 5.3.6.1. Canada Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    4. 5.4. Europe
      1. 5.4.1. Europe Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
        1. 5.4.1.1. Europe Fabry Disease Treatment Market, by Country, 2016 - 2026 (USD Million)
      2. 5.4.2. Europe Fabry Disease Treatment Market, by Drugs, 2016 – 2026
        1. 5.4.2.1. Europe Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      3. 5.4.3. Europe Fabry Disease Treatment Market, by Treatment, 2016 – 2026
        1. 5.4.3.1. Europe Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      4. 5.4.4. Europe Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026
        1. 5.4.4.1. Europe Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      5. 5.4.5. Germany
        1. 5.4.5.1. Germany Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      6. 5.4.6. France
        1. 5.4.6.1. France Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      7. 5.4.7. U.K.
        1. 5.4.7.1. U.K. Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      8. 5.4.8. Italy
        1. 5.4.8.1. Italy Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      9. 5.4.9. Spain
        1. 5.4.9.1. Spain Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      10. 5.4.10. Rest of Europe
        1. 5.4.10.1. Rest of Europe Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    5. 5.5. Asia Pacific
      1. 5.5.1. Asia Pacific Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
        1. 5.5.1.1. Asia Pacific Fabry Disease Treatment Market, by Country, 2016 - 2026 (USD Million)
      2. 5.5.2. Asia Pacific Fabry Disease Treatment Market, by Drugs, 2016 – 2026
        1. 5.5.2.1. Asia Pacific Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      3. 5.5.3. Asia Pacific Fabry Disease Treatment Market, by Treatment, 2016 – 2026
        1. 5.5.3.1. Asia Pacific Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      4. 5.5.4. Asia Pacific Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026
        1. 5.5.4.1. Asia Pacific Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      5. 5.5.5. China
        1. 5.5.5.1. China Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      6. 5.5.6. Japan
        1. 5.5.6.1. Japan Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      7. 5.5.7. India
        1. 5.5.7.1. India Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      8. 5.5.8. South Korea
        1. 5.5.8.1. South Korea Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      9. 5.5.9. South-East Asia
        1. 5.5.9.1. South-East Asia Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      10. 5.5.10. Rest of Asia Pacific
        1. 5.5.10.1. Rest of Asia Pacific Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    6. 5.6. Latin America
      1. 5.6.1. Latin America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
        1. 5.6.1.1. Latin America Fabry Disease Treatment Market, by Country, 2016 - 2026 (USD Million)
      2. 5.6.2. Latin America Fabry Disease Treatment Market, by Drugs, 2016 – 2026
        1. 5.6.2.1. Latin America Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      3. 5.6.3. Latin America Fabry Disease Treatment Market, by Treatment, 2016 – 2026
        1. 5.6.3.1. Latin America Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      4. 5.6.4. Latin America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026
        1. 5.6.4.1. Latin America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      5. 5.6.5. Brazil
        1. 5.6.5.1. Brazil Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      6. 5.6.6. Mexico
        1. 5.6.6.1. Mexico Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      7. 5.6.7. Rest of Latin America
        1. 5.6.7.1. Rest of Latin America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    7. 5.7. The Middle-East and Africa
      1. 5.7.1. The Middle-East and Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
        1. 5.7.1.1. The Middle-East and Africa Fabry Disease Treatment Market, by Country, 2016 - 2026 (USD Million)
      2. 5.7.2. The Middle-East and Africa Fabry Disease Treatment Market, by Drugs, 2016 – 2026
        1. 5.7.2.1. The Middle-East and Africa Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      3. 5.7.3. The Middle-East and Africa Fabry Disease Treatment Market, by Treatment, 2016 – 2026
        1. 5.7.3.1. The Middle-East and Africa Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      4. 5.7.4. The Middle-East and Africa Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026
        1. 5.7.4.1. The Middle-East and Africa Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      5. 5.7.5. GCC Countries
        1. 5.7.5.1. GCC Countries Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      6. 5.7.6. South Africa
        1. 5.7.6.1. South Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      7. 5.7.7. Rest of Middle-East Africa
        1. 5.7.7.1. Rest of Middle-East Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
  6. Chapter 6 Fabry Disease Treatment Market – Competitive Landscape
    1. 6.1. Competitor Market Share – Revenue
    2. 6.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    3. 6.3. Strategic Developments
      1. 6.3.1. Acquisitions and Mergers
      2. 6.3.2. New Products
      3. 6.3.3. Research & Development Activities
  7. Chapter 7 Company Profiles
    1. 7.1. Sanofi S.A.
      1. 7.1.1. Company Overview
      2. 7.1.2. Product/Service Portfolio
      3. 7.1.3. Sanofi S.A. Sales, Revenue, and Gross Margin
      4. 7.1.4. Sanofi S.A. Revenue and Growth Rate
      5. 7.1.5. Sanofi S.A. Market Share
      6. 7.1.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    2. 7.2. Amicus Therapeutics Inc.
      1. 7.2.1. Company Overview
      2. 7.2.2. Product/Service Portfolio
      3. 7.2.3. Amicus Therapeutics Inc. Sales, Revenue, and Gross Margin
      4. 7.2.4. Amicus Therapeutics Inc. Revenue and Growth Rate
      5. 7.2.5. Amicus Therapeutics Inc. Market Share
      6. 7.2.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    3. 7.3. Avrobio Inc.
      1. 7.3.1. Company Overview
      2. 7.3.2. Product/Service Portfolio
      3. 7.3.3. Avrobio Inc. Sales, Revenue, and Gross Margin
      4. 7.3.4. Avrobio Inc. Revenue and Growth Rate
      5. 7.3.5. Avrobio Inc. Market Share
      6. 7.3.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    4. 7.4. Shire Plc.
      1. 7.4.1. Company Overview
      2. 7.4.2. Product/Service Portfolio
      3. 7.4.3. Shire Plc. Sales, Revenue, and Gross Margin
      4. 7.4.4. Shire Plc. Revenue and Growth Rate
      5. 7.4.5. Shire Plc. Market Share
      6. 7.4.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    5. 7.5. Idorsia Pharmaceuticals Ltd.
      1. 7.5.1. Company Overview
      2. 7.5.2. Product/Service Portfolio
      3. 7.5.3. Idorsia Pharmaceuticals Ltd. Sales, Revenue, and Gross Margin
      4. 7.5.4. Idorsia Pharmaceuticals Ltd. Revenue and Growth Rate
      5. 7.5.5. Idorsia Pharmaceuticals Ltd. Market Share
      6. 7.5.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    6. 7.6. Greenovation Biotech GmbH
      1. 7.6.1. Company Overview
      2. 7.6.2. Product/Service Portfolio
      3. 7.6.3. Greenovation Biotech GmbH Sales, Revenue, and Gross Margin
      4. 7.6.4. Greenovation Biotech GmbH Revenue and Growth Rate
      5. 7.6.5. Greenovation Biotech GmbH Market Share
      6. 7.6.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    7. 7.7. ISU Abxis Co Ltd.
      1. 7.7.1. Company Overview
      2. 7.7.2. Product/Service Portfolio
      3. 7.7.3. ISU Abxis Co Ltd. Sales, Revenue, and Gross Margin
      4. 7.7.4. ISU Abxis Co Ltd. Revenue and Growth Rate
      5. 7.7.5. ISU Abxis Co Ltd. Market Share
      6. 7.7.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    8. 7.8. Moderna Therapeutics Inc.
      1. 7.8.1. Company Overview
      2. 7.8.2. Product/Service Portfolio
      3. 7.8.3. Moderna Therapeutics Inc. Sales, Revenue, and Gross Margin
      4. 7.8.4. Moderna Therapeutics Inc. Revenue and Growth Rate
      5. 7.8.5. Moderna Therapeutics Inc. Market Share
      6. 7.8.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    9. 7.9. JCR Pharmaceuticals Co Ltd
      1. 7.9.1. Company Overview
      2. 7.9.2. Product/Service Portfolio
      3. 7.9.3. JCR Pharmaceuticals Co Ltd Sales, Revenue, and Gross Margin
      4. 7.9.4. JCR Pharmaceuticals Co Ltd Revenue and Growth Rate
      5. 7.9.5. JCR Pharmaceuticals Co Ltd Market Share
      6. 7.9.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    10. 7.10. Protalix Biotherapeutics Inc.
      1. 7.10.1. Company Overview
      2. 7.10.2. Product/Service Portfolio
      3. 7.10.3. Protalix Biotherapeutics Inc. Sales, Revenue, and Gross Margin
      4. 7.10.4. Protalix Biotherapeutics Inc. Revenue and Growth Rate
      5. 7.10.5. Protalix Biotherapeutics Inc. Market Share
      6. 7.10.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
  8. Chapter 8 Fabry Disease Treatment — Industry Analysis
    1. 8.1. Introduction and Taxonomy
    2. 8.2. Fabry Disease Treatment Market – Key Trends
      1. 8.2.1. Market Drivers
      2. 8.2.2. Market Restraints
      3. 8.2.3. Market Opportunities
    3. 8.3. Value Chain Analysis
    4. 8.4. Key Mandates and Regulations
    5. 8.5. Technology Roadmap and Timeline
    6. 8.6. Fabry Disease Treatment Market – Attractiveness Analysis
      1. 8.6.1. By Drugs
      2. 8.6.2. By Treatment
      3. 8.6.3. By Route of Administration
      4. 8.6.4. By Region
  9. Chapter 9 Industrial Chain, Sourcing Strategy, and Downstream Buyers
    1. 9.1. Fabry Disease Treatment Industrial Chain Analysis
    2. 9.2. Downstream Buyers
    3. 9.3. Distributors/Traders List
  10. Chapter 10 Marketing Strategy Analysis
    1. 10.1. Marketing Channel
    2. 10.2. Direct Marketing
    3. 10.3. Indirect Marketing
    4. 10.4. Marketing Channel Development Trends
    5. 10.5. Economic/Political Environmental Change
  11. Chapter 11 Report Conclusion & Key Insights
    1. 11.1. Key Insights from Primary Interviews & Surveys Respondents
    2. 11.2. Key Takeaways from Analysts, Consultants, and Industry Leaders
  12. Chapter 12 Research Approach & Methodology
    1. 12.1. Report Description
    2. 12.2. Research Scope
    3. 12.3. Research Methodology
      1. 12.3.1. Secondary Research
      2. 12.3.2. Primary Research
      3. 12.3.3. Statistical Models
        1. 12.3.3.1. Company Share Analysis Model
        2. 12.3.3.2. Revenue Based Modeling
      4. 12.3.4. Research Limitations

      List of Figures

      Fig.1	Product Picture of Fabry Disease Treatment
Fig.2	Global Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.3	Global Fabry Disease Treatment Market Absolute Revenue Opportunity, 2016 – 2026 (USD Million)
Fig.4	Global Fabry Disease Treatment Market Incremental Revenue Opportunity, 2020 – 2026 (USD Million)
Fig.5	Global Fabry Disease Treatment Market Share, by Drugs, 2019 & 2026 (USD Million)
Fig.6	Global Agalsidase Beta Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.7	Global Migalastat Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.8	Global Pipeline Drugs Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.9	Global Fabry Disease Treatment Market Share, by Treatment, 2019 & 2026 (USD Million)
Fig.10	Global Enzyme Replacement Therapy (ERT) Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.11	Global Chaperone Treatment Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.12	Global Substrate Reduction Therapy (SRT) Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.13	Global Others Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.14	Global Fabry Disease Treatment Market Share, by Route of Administration, 2019 & 2026 (USD Million)
Fig.15	Global Oral Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.16	Global Intravenous Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.17	Global Fabry Disease Treatment Market Share, by Region, 2019 & 2026 (USD Million)
Fig.18	North America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.19	U.S. Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.20	Canada Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.21	Europe Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.22	Germany Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.23	France Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.24	U.K. Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.25	Italy Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.26	Spain Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.27	Rest of Europe Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.28	Asia Pacific Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.29	China Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.30	Japan Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.31	India Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.32	South  Korea Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.33	South-East Asia Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.34	Rest of Asia Pacific Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.35	Latin America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.36	Brazil Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.37	Mexico Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.38	Rest of Latin America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.39	The Middle-East and Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.40	GCC Countries Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.41	South Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.42	Rest of Middle-East Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
Fig.43	Competitor Market Share – Revenue
Fig.44	Sanofi S.A. Revenue and Growth Rate
Fig.45	Sanofi S.A. Market Share
Fig.46	Amicus Therapeutics Inc. Revenue and Growth Rate
Fig.47	Amicus Therapeutics Inc. Market Share
Fig.48	Avrobio Inc. Revenue and Growth Rate
Fig.49	Avrobio Inc. Market Share
Fig.50	Shire Plc. Revenue and Growth Rate
Fig.51	Shire Plc. Market Share
Fig.52	Idorsia Pharmaceuticals Ltd. Revenue and Growth Rate
Fig.53	Idorsia Pharmaceuticals Ltd. Market Share
Fig.54	Greenovation Biotech GmbH Revenue and Growth Rate
Fig.55	Greenovation Biotech GmbH Market Share
Fig.56	ISU Abxis Co Ltd. Revenue and Growth Rate
Fig.57	ISU Abxis Co Ltd. Market Share
Fig.58	Moderna Therapeutics Inc. Revenue and Growth Rate
Fig.59	Moderna Therapeutics Inc. Market Share
Fig.60	JCR Pharmaceuticals Co Ltd Revenue and Growth Rate
Fig.61	JCR Pharmaceuticals Co Ltd Market Share
Fig.62	Protalix Biotherapeutics Inc. Revenue and Growth Rate
Fig.63	Protalix Biotherapeutics Inc. Market Share
Fig.64	Market Dynamics
Fig.65	Global Fabry Disease Treatment – Value Chain Analysis
Fig.66	Key Mandates and Regulations
Fig.67	Technology Roadmap and Timeline
Fig.68	Market Attractiveness Analysis – By Drugs
Fig.69	Market Attractiveness Analysis – By Treatment
Fig.70	Market Attractiveness Analysis – By Route of Administration
Fig.71	Market Attractiveness Analysis – By Region
Fig.72	Fabry Disease Treatment Industrial Chain Analysis
Fig.73	Market Channels
Fig.74	Marketing Channel Development Trend
Fig.75	Growth in World Gross Product, 2008-2018

      List of Tables

      Table 1	Global Fabry Disease Treatment Market, 2019 & 2026 (USD Million)
Table 2	Global Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
Table 3	Global Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
Table 4	Global Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
Table 5	Global Fabry Disease Treatment Market, by Region, 2016 – 2026 (USD Million)
Table 6	North America Fabry Disease Treatment Market, by Country, 2016 – 2026 (USD Million)
Table 7	North America Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
Table 8 North America Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
Table 9 North America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
Table 10 Europe Fabry Disease Treatment Market, by Country, 2016 – 2026 (USD Million)
Table 11 Europe Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
Table 12 Europe Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
Table 13 Europe Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
Table 14 Asia Pacific Fabry Disease Treatment Market, by Country, 2016 – 2026 (USD Million)
Table 15 Asia Pacific Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
Table 16 Asia Pacific Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
Table 17 Asia Pacific Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
Table 18 Latin America Fabry Disease Treatment Market, by Country, 2016 – 2026 (USD Million)
Table 19 Latin America Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
Table 20 Latin America Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
Table 21 Latin America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
Table 22 The Middle-East and Africa Fabry Disease Treatment Market, by Country, 2016 – 2026 (USD Million)
Table 23 The Middle-East and Africa Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
Table 24 The Middle-East and Africa Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
Table 25 The Middle-East and Africa Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
Table 26 Global Fabry Disease Treatment Market - Company Revenue Analysis, 2016 – 2019 (USD Million)
Table 27 Global Fabry Disease Treatment Market - Company Revenue Share Analysis, 2016 – 2019 (%)
Table 28 Acquisitions and Mergers
Table 29 Market Drivers – Impact Analysis
Table 30 Market Restraints
Table 31 Market Opportunities
Table 32 Major Buyers of Fabry Disease Treatment
Table 33 Distributors/Traders of Fabry Disease Treatment by Region

Industry Major Market Players

  • ISU Abxis Co Ltd.
  • Greenovation Biotech GmbH
  • Amicus Therapeutics Inc.
  • Avrobio Inc.
  • Shire Plc.
  • Sanofi S.A.
  • Moderna Therapeutics Inc.
  • JCR Pharmaceuticals
  • Protalix Biotherapeutics Inc.
  • Idorsia Pharmaceuticals Ltd.

paypal
Copyright © 2023 - 2024, All Rights Reserved, Facts and Factors